Pulmotect Convenes Inaugural Scientific Advisory Board
Pulmotect, Inc., a clinical-stage biotechnology company developing and commercializing a fast-acting inhalant designed to treat respiratory infections, today announced the formation of a Scientific Advisory Board comprised of academic and industry experts in respiratory research and care. Members... - June 02, 2017
Pulmotect Selected to Exhibit at 2017 BIO International Convention “Innovation Zone”
Pulmotect, Inc., a clinical-stage biotechnology company developing and commercializing an inhalant designed to treat respiratory infections, was selected by the National Science Foundation (NSF) and the National Institutes of Health (NIH) to be featured in an Innovation Zone at the 2017 BIO... - May 20, 2017
US China Innovation and Investment Summit Panel on Biopharmaceuticals to Feature Pulmotect CEO
Molfino, a respiratory medicine specialist, will provide his perspective on balancing the costs of developing and delivering innovative technologies, drug safety and regulatory issues, important learnings to date and the future outlook of therapeutics in modern healthcare. - May 10, 2017